EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY 4.0

Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review

Gillian Parker iD, Sarah Hunter, Samer Ghazi, Robin Z Hayeems, Francois Rousseau, Fiona A Miller

PLOS ONE · 10.03.2023 · 18 (3) · e0280582

DOI: 10.1371/journal.pone.0280582 ↗

Kurz gefasst

Scoping Review in der Zeitschrift PLOS ONE, online erschienen am 10.03.2023. Verfasst von Gillian Parker und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Decision impact studies have become increasingly prevalent in cancer prognostic research in recent years. These studies aim to evaluate the impact of a genomic test on decision-making and appear to be a new form of evidence of clinical utility. The objectives of this review were to identify and characterize decision impact studies in genomic medicine in cancer care and categorize the types of clinical utility outcomes reported.

Methods

We conducted a search of four databases, Medline, Embase, Scopus and Web of Science, from inception to June 2022. Empirical studies that reported a “decision impact” assessment of a genomic assay on treatment decisions or recommendations for cancer patients were included. We followed scoping review methodology and adapted the Fryback and Thornbury Model to collect and analyze data on clinical utility. The database searches identified 1803 unique articles for title/abstract screening; 269 articles moved to full-text review.

Results

87 studies met inclusion criteria. All studies were published in the last 12 years with the majority for breast cancer (72%); followed by other cancers (28%) (lung, prostate, colon). Studies reported on the impact of 19 different proprietary (18) and generic (1) assays. Across all four levels of clinical utility, outcomes were reported for 22 discrete measures, including the impact on provider/team decision-making (100%), provider confidence (31%); change in treatment received (46%); patient psychological impacts (17%); and costing or savings impacts (21%). Based on the data synthesis, we created a comprehensive table of outcomes reported for clinical utility.

Conclusions

This scoping review is a first step in understanding the evolution and uses of decision impact studies and their influence on the integration of emerging genomic technologies in cancer care. The results imply that DIS are positioned to provide evidence of clinical utility and impact clinical practice and reimbursement decision-making in cancer care.

Systematic review registration

Open Science Framework osf.io/hm3jr .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMaleHumansPrognosisProstateGenomics

Autor:innen und Institutionen

  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
  • Child Health Evaluative Sciences Program, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Department of Molecular Biology, Medical Biochemistry, and Pathology, Faculty of Medicine, Université Laval, Québec City, Québec, Canada.

ORCID-Profile: Gillian Parker

Förderung

  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Parker, G., Hunter, S., Ghazi, S., Hayeems, R. Z., Rousseau, F., & Miller, F. A. (2023). Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. PLOS ONE, 18(3), e0280582. https://doi.org/10.1371/journal.pone.0280582

Vancouver

Parker G, Hunter S, Ghazi S, Hayeems RZ, Rousseau F, Miller FA. Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review. PLOS ONE. 2023;18(3):e0280582. doi:10.1371/journal.pone.0280582

BibTeX
@article{Parker2023,
  author = {Parker, Gillian and Hunter, Sarah and Ghazi, Samer and Hayeems, Robin Z and Rousseau, Francois and Miller, Fiona A},
  title = {Decision impact studies, evidence of clinical utility for genomic assays in cancer: A scoping review},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {e0280582},
  doi = {10.1371/journal.pone.0280582}
}
Kostenlos starten →